clinical trial · NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin LymphomaSC MosunetuzumabIV GlofitamabIberdomideGolcadomideObinutuzumabTocilizumab
brief summary
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
started
Oct 26, 2022
primary completion
Sep 15, 2029
completion
Sep 15, 2029
last updated
Jun 12, 2026
official title
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol